Abiomed Inc. (NASDAQ:ABMD) previous close was $282.27 while the outstanding shares total 45.20M. The firm has a beta of 1.31, a 12-month trailing P/E ratio of 57.90, and a growth ratio of 3.39. ABMD’s shares traded higher over the last trading session, gaining 1.27% on 05/27/21. The shares fell to a low of $278.74 before closing at $285.85. Intraday shares traded counted 0.54 million, which was -95.93% lower than its 30-day average trading volume of 273.12K. The stock’s Relative Strength Index (RSI) is 44.35, with weekly volatility at 2.12% and ATR at 9.13. The ABMD stock’s 52-week price range has touched low of $200.46 and a $387.40 high.
Investors have identified the Medical Devices company Abiomed Inc. as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around $12.76 billion, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.
Abiomed Inc. (ABMD) Fundamentals that are to be considered.
When analyzing a stock, the first fundamental thing to take into account is the balance sheet. How healthy the balance sheet of a company is will determine if the company will be able to carry out all its financial and non-financial obligations and also keep the faith of its investors. In terms of their assets, the company currently has 787.97 million total, with 128.97 million as their total liabilities.
ABMD were able to record 221.19 million as free cash flow during the 07/29/2021 quarter of the year, this saw their quarterly net cash flow reduce by 40.37 million. In cash movements, the company had a total of 274.58 million as operating cash flow.
Potential earnings growth for Abiomed Inc. (ABMD)
In order to determine the future investment potential for this stock, we will have to analyze key trends that affect it. During the 07/29/2021 quarter of the year, Abiomed Inc. recorded a total of 241.25 million in revenue. This figure implies that they witnessed a quarterly year/year change in their earnings with 14.34% coming in sequential stages and their sales for the 07/29/2021 quarter increasing by 3.97%.
What matters though is how it ends. When the core data for the company is broken down, then the stock sounds interesting. The company spent 46.08 million trying to sell their products during the last quarter, with the result yielding a gross income of 195.17 million. This allows shareholders to hold on to 45.20M with the recently reported earning now reading 1.26 cents per share. This is a figure that compared to analyst’s prediction for their 07/29/2021 (1.24 cents a share).
Having a look at the company’s valuation, the company is expected to record 5.17 total earnings per share during the next fiscal year. It is very important though to remember that the importance of trend far outweighs that of outlook. This analysis has been great and getting further updates on ABMD sounds very interesting.
Is the stock of ABMD attractive?
In related news, Director, SUTTER MARTIN P sold 3,750 shares of the company’s stock in a transaction that recorded on May 19. The sale was performed at an average price of 267.44, for a total value of 1,002,900. As the sale deal closes, the Director, SUTTER MARTIN P now sold 3,750 shares of the company’s stock, valued at 1,000,200. Also, Director, SUTTER MARTIN P sold 3,750 shares of the company’s stock in a deal that was recorded on Feb 17. The shares were price at an average price of 314.01 per share, with a total market value of 1,177,538. Following this completion of acquisition, the Director, SUTTER MARTIN P now holds 3,750 shares of the company’s stock, valued at 1,240,012. In the last 6 months, insiders have changed their ownership in shares of company stock by 1.20%.
4 out of 9 analysts covering the stock have rated it a Buy, while 4 have maintained a Hold recommendation on Abiomed Inc.. 1 analysts has assigned a Sell rating on the ABMD stock. The 12-month mean consensus price target for the company’s shares has been set at $374.00.